Nivolumab for the treatment of bladder cancer

Volume: 17, Issue: 10, Pages: 1309 - 1315
Published: Jul 24, 2017
Abstract
Introduction: The checkpoint inhibitor nivolumab has recently demonstrated effectiveness against metatstatic urothelial carcinoma. Nivolumab is a fully human monoclonal antibody blocking PD-1 and thereby enhancing antitumour immune mechanisms.Areas covered: In this review, the authors describe the treatment of metastatic bladder cancer with nivolumab against the background of the standard treatment with cisplatin-based chemotherapy which can...
Paper Details
Title
Nivolumab for the treatment of bladder cancer
Published Date
Jul 24, 2017
Volume
17
Issue
10
Pages
1309 - 1315
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.